Study guide
12.3 Acute Ureteric Colic & Medical Expulsive Therapy
FEBU Part 1 Written European Board of Urology
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Introduction & Exam Strategy
1.1 FEBU Part 1 Examination Structure & Logistics 1.2 EAU Guidelines Framework & Standard Setting 1.3 Clinical Decision-Making & MCQ Strategy 1.4 Professionalism and Safe Practice
2 Chapter 2: Genitourinary Anatomy & Renal Physiology
2.1 Upper Tract Anatomy & Retroperitoneal Relationships 2.2 Lower Urinary Tract Anatomy & Neuroanatomy 2.3 Renal Physiology, Glomerular Filtration & Acid-Base Balance
3 Chapter 3: Urological Pharmacology & Diagnostic Imaging
3.1 Lower Urinary Tract Pharmacotherapy 3.2 Antimicrobial Stewardship & Perioperative Care 3.3 Diagnostic Modalities: Ultrasound, CT, mpMRI & Nuclear Medicine
4 Chapter 4: Prostate Cancer: Diagnosis & Risk Stratification
4.1 PSA Kinetics, Biomarkers & Risk Assessment 4.2 Multiparametric MRI (PI-RADS) & Biopsy Strategies 4.3 Histopathological Grading (ISUP Gleason) & Staging
5 Chapter 5: Prostate Cancer: Localized & Advanced Management
5.1 Active Surveillance & Watchful Waiting 5.2 Radical Prostatectomy & Radiation Therapy 5.3 Biochemical Recurrence & Salvage Therapies 5.4 Metastatic & Castration-Resistant Prostate Cancer (CRPC)
6 Chapter 6: Bladder Cancer: Non-Muscle Invasive (NMIBC)
6.1 TURBT Technique & Pathological Staging 6.2 EAU Risk Stratification for NMIBC 6.3 Intravesical Chemotherapy & BCG Immunotherapy
7 Chapter 7: Muscle-Invasive Bladder Cancer & Upper Tract Urothelial Carcinoma
7.1 Muscle-Invasive Bladder Cancer (MIBC) Staging & Neoadjuvant Therapy 7.2 Radical Cystectomy & Urinary Diversion 7.3 Upper Tract Urothelial Carcinoma (UTUC)
8 Chapter 8: Renal Cell Carcinoma & Adrenal Neoplasms
8.1 Histological Subtypes, Genetics & Staging of RCC 8.2 Localized RCC: Nephron-Sparing Surgery & Radical Nephrectomy 8.3 Metastatic RCC & Targeted / Immunotherapy Regimens 8.4 Adrenal Masses & Incidentalomas
9 Chapter 9: Testicular Germ Cell Tumours & Penile Cancer
9.1 Testicular Cancer Diagnosis, Staging & Tumour Markers 9.2 Management of Seminoma (Stage I to Metastatic) 9.3 Management of Non-Seminoma (Stage I to Metastatic) 9.4 Penile Cancer: Staging, Organ-Sparing & Lymphadenectomy
10 Chapter 10: Benign Prostatic Hyperplasia & Lower Urinary Tract Symptoms
10.1 BPH Pathophysiology, Natural History & Clinical Evaluation 10.2 Medical Management of Male LUTS / BPO 10.3 Interventional & Surgical Management of BPO
11 Chapter 11: Functional Urology, Incontinence & Neuro-Urology
11.1 Urinary Incontinence in Men and Women, Fistulae & Urethral Diverticula 11.2 Overactive Bladder, Bladder Pain Syndrome & Pelvic Organ Prolapse 11.3 Neurogenic Lower Urinary Tract Dysfunction (NLUTD) 11.4 Urodynamic Studies: Indications, Technique & Interpretation
12 Chapter 12: Urolithiasis: Evaluation & Medical Management
12.1 Stone Pathophysiology & Risk Factors 12.2 Metabolic Evaluation & Dietary/Medical Stone Prevention 12.3 Acute Ureteric Colic & Medical Expulsive Therapy
13 Chapter 13: Endourology & Interventional Stone Management
13.1 Shock Wave Lithotripsy (SWL) 13.2 Ureteroscopy (URS) & Retrograde Intrarenal Surgery (RIRS) 13.3 Percutaneous Nephrolithotomy (PCNL) & Endourological Safety
14 Chapter 14: Infections, Andrology & Male Infertility
14.1 Localised & Systemic UTIs, Pyelonephritis, Urosepsis & Specific Infections 14.2 Prostatitis, Epididymo-Orchitis & Fournier Gangrene 14.3 Male Infertility: Evaluation & Surgical Management 14.4 Erectile Dysfunction, Peyronie Disease, Priapism & Gender-Affirming Surgery
15 Chapter 15: Paediatric Urology, Trauma & Renal Transplantation
15.1 Cryptorchidism, Hypospadias & PUJO 15.2 Vesicoureteral Reflux, Posterior Urethral Valves & Nocturnal Enuresis 15.3 Genitourinary Trauma: Kidney, Bladder & Urethra 15.4 Renal Failure, Dialysis Indications & Renal Transplantation
12.3 Acute Ureteric Colic & Medical Expulsive Therapy
Key Takeaways Explain This Topic AI
EAU recommends ultrasound as initial imaging, followed by non-contrast CT to confirm suspected stones in adults with acute flank pain. Use low-dose CT when suitable; it defines stone size, site, density and obstruction, with accuracy affected by protocol, body habitus and very small stones.
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs: diclofenac, ketorolac, indomethacin) are the first-line analgesics per EAU Guidelines, providing superior and longer-lasting pain relief with fewer adverse events compared to opioids by reducing renal blood flow and ureteral smooth muscle spasm.
Obstructing ureteric calculus with concurrent urinary tract infection or sepsis is an absolute urological emergency requiring urgent decompression (retrograde JJ stenting or percutaneous nephrostomy); primary definitive stone extraction in this setting is strictly contraindicated.
Offer an alpha-blocker such as tamsulosin 0.4 mg/day as an off-label option for selected distal ureteral stones 5–10 mm when active removal is not indicated. Benefit is greatest for stones>5 mm; stop MET for infection, refractory pain or deteriorating renal function.
Last updated: November 2026
Acute Ureteric Colic & Medical Expulsive Therapy
Acute ureteric colic is among the most severe pain syndromes encountered in emergency medicine. Successful management requires rapid diagnosis, effective non-opioid analgesia, timely identification of life-threatening obstructive complications requiring emergency surgical decompression, and evidence-based selection between conservative observation, medical expulsive therapy, and endourological intervention.
Clinical Presentation and Pathophysiology of Ureteric Colic
Acute ureteric colic is triggered by sudden acute intraluminal obstruction of the ureter by a migrating calculus.
Pathophysiological Phases of Obstruction
Early Phase (Hours 0 to 1.5–2) : Acute intraluminal stone impaction impedes urine outflow. Proximal ureteral and renal pelvic pressure surges from physiological baselines of 5–10 mmHg up to 50–70 mmHg . This acute stretching of the pelvicalyceal system stimulates local prostaglandin ( P G E 2 PGE_2 PG E 2 and P G I 2 PGI_2 PG I 2 ) synthesis. Prostaglandins induce intense afferent arteriolar vasodilation , causing transiently increased renal blood flow (hyperemia). Obstruction raises tubular backpressure and opposes filtration, while pelvic/capsular stretching and hyperperistalsis produce pain.
Intermediate Phase (Hours 2 to 5) : Intrarenal hydrostatic pressure remains elevated, but renal blood flow begins to decline due to progressive efferent arteriolar and pre-glomerular vasoconstriction mediated by thromboxane A 2 A_2 A 2 and angiotensin II.
Late Chronic Phase (Beyond 5 to 24 Hours) : Both renal blood flow and intraluminal pressure progressively decline. Glomerular filtration drops markedly. If obstruction remains uncorrected, progressive ischemic parenchymal atrophy and renal injury can become irreversible. Duration, completeness, infection and baseline renal function affect recovery; do not treat 2–4 weeks as a guaranteed safe waiting period.
Pain Characteristics and Radiation Patterns
The agonizing, crescendo-decrescendo flank pain originates from tension mechanoreceptors within the renal pelvis and capsule (innervated by sympathetic fibers via T10–L1 spinal segments):
Upper Ureteral and Pelviureteric Junction Calculi : Pain localizes to the costovertebral angle and flank, radiating along the subcostal margin to the ipsilateral upper abdomen.
Mid-Ureteral Calculi (Crossing the Iliac Vessels) : Radiates to the lower abdominal quadrant, frequently mimicking acute appendicitis (on the right) or acute diverticulitis (on the left).
Distal Ureteral and Vesicoureteric Junction (VUJ) Calculi : Radiates along the ilioinguinal and genitofemoral nerves into the ipsilateral groin, testicle, or scrotum in males, and the labium majus in females. Intramural or juxtavesical stones irritate bladder trigone mechanoreceptors, producing marked lower urinary tract symptoms (LUTS) : severe frequency, urgency, dysuria, and strangury, frequently misdiagnosed as acute bacterial cystitis.
Note
Microscopic or gross hematuria is present in approximately 85% to 90% of acute ureteric colic presentations. However, in 10% to 15% of cases , urinalysis shows completely absent hematuria . Absence of hematuria neither excludes a stone nor proves complete obstruction; evaluate the full clinical and imaging picture.
Diagnostic Imaging Workup
Establishing an accurate diagnosis requires rapid, high-resolution imaging to confirm calculus presence, size, location, and secondary obstructive changes.
Non-Contrast Computed Tomography (NCCT / CT-KUB)
Non-contrast CT (NCCT / CT-KUB) is the confirmatory test for suspected acute ureteric stones in adults after initial ultrasound under EAU guidance. Obtain immediate imaging with fever, a solitary kidney or diagnostic uncertainty; analgesia must not be delayed. Use an appropriate low-dose protocol when suitable.
Key Diagnostic Parameters Provided by NCCT :
Precise Calculus Dimensions : Measured accurately in three orthogonal planes (axial, coronal, and sagittal). Stone size is defined by its greatest diameter.
Anatomical Location : Exact level of impaction (PUJ, proximal, mid, distal, or VUJ).
Internal Stone Density (Attenuation in Hounsfield Units, HU) : Helps estimate composition and SWL suitability, but HU ranges overlap; density alone does not reliably distinguish every stone type. Dual-energy CT can separate uric-acid-containing from calcium stones.
Skin-to-Stone Distance (SSD) : Measured along the acoustic shock wave path; SSD > 10 > 10 > 10 cm is an independent predictor of SWL failure.
Secondary Signs of Obstruction : Perinephric fat stranding (fluid transudation into Gerota's fascia), hydroureteronephrosis, renal enlargement / nephromegaly , and the tissue rim sign (periureteral soft-tissue halo of edema indicating localized inflammatory impaction).
Low-Dose Protocols : Modern low-dose CT protocols deliver an effective radiation dose < 1.5 − 3.0 < 1.5 - 3.0 < 1.5 − 3.0 mSv (comparable to a standard plain abdominal radiograph series) with performance dependent on protocol, body habitus and stone size. EAU cites pooled sensitivity 93.1% and specificity 96.6% for low-dose CT; small stones can be missed.
Ultrasonography (US) and Plain Abdominal Radiography (KUB)
Ultrasonography : EAU's initial imaging tool for suspected stones, particularly important in pregnancy and children ; adult acute-flank-pain evaluation generally proceeds to NCCT confirmation as indicated. Ultrasound has high sensitivity for detecting pelvicalyceal dilatation / hydronephrosis ( > 85 % > 85\% > 85% ), but poor sensitivity for direct ureteral stone visualization ( 45 − 60 % 45 - 60\% 45 − 60% , restricted primarily to the PUJ and the UVJ through a full bladder acoustic window).
Plain KUB Radiograph : Sensitivity is only 50 − 60 % 50 - 60\% 50 − 60% ; obscured by overlying bowel gas, fecal matter, and bony pelvic architecture. Cannot detect radiolucent calculi. Its primary utility is baseline assessment prior to planned Shock Wave Lithotripsy (to confirm fluoroscopic visibility) and interval surveillance of known radio-opaque stones.
Acute Analgesic Management
Prompt pain relief is the first therapeutic imperative in acute ureteric colic.
First-Line Analgesia: Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
Per EAU Guidelines, NSAIDs are the first analgesic choice when clinically appropriate , accounting for cardiovascular risk, renal function and other contraindications for acute renal colic:
Preferred Agents and Dosing : Diclofenac (50–75 mg IV/IM or 100 mg PR), Ketorolac (15–30 mg IV), Indomethacin (50–100 mg PR), or Ibuprofen (600–800 mg PO).
Pharmacological Mechanism :
Inhibit cyclooxygenase (COX-1 and COX-2) enzymes, blocking the synthesis of intrarenal vasodilatory prostaglandins ( P G E 2 PGE_2 PG E 2 and P G I 2 PGI_2 PG I 2 ).
Induce pre-glomerular afferent arteriolar vasoconstriction, dampening renal blood flow and decreasing glomerular filtration rate.
Consequently lower intrarenal pelvicalyceal hydrostatic pressure and decrease mechanical stretching of pelvic pain mechanoreceptors.
Directly reduce local ureteral edema, inflammation, and hyperperistaltic smooth muscle spasm.
Clinical Superiority over Opioids : Cochrane meta-analyses and prospective randomized trials demonstrate that NSAIDs achieve faster, more sustained pain reduction , lower requirements for rescue analgesia, and significantly lower rates of adverse events (specifically reducing nausea, vomiting, dizziness, and sedation) compared to opioids.
Contraindications : Severe chronic kidney disease (eGFR < 30 < 30 < 30 mL/min), acute kidney injury with hypovolemia, active gastrointestinal peptic ulcer disease, severe heart failure, and third-trimester pregnancy.
Second-Line Analgesia: Opioids
Agents : Morphine , Piritramide , Hydromorphone , or Pethidine .
Clinical Indications : Reserved strictly for patients with active contraindications to NSAIDs or as rescue analgesia for refractory breakthrough pain.
Adverse Effects : High incidence of nausea and vomiting (aggravating existing autonomic colic symptoms), respiratory depression, constipation, and physical dependence. Pethidine should be avoided due to neurotoxicity from its active metabolite, norpethidine.
Antispasmodics (Spasmolytics)
Hyoscine butylbromide (Buscopan) and other anticholinergic spasmolytics are not a substitute for effective colic analgesia; EAU notes that adding antispasmodics to NSAIDs does not improve pain control .
Indications for Urgent Drainage or Stone Intervention
While the majority of acute colic episodes can be managed conservatively, infection with obstruction or anuria requires urgent drainage. With refractory pain or threatened renal function, urgent relief may involve drainage or, when infection is absent, stone removal. +------------------------------------------------------------------------------------------------+
- | INDICATIONS FOR URGENT UROLOGICAL INTERVENTION |
- | |
- | 1. Obstructive Pyelonephritis / Urosepsis (Fever, Rigors, Hemodynamic Instability) |
- | 2. Solitary Kidney with Obstructing Calculus (Imminent Anephric Renal Failure) |
- | 3. Bilateral Obstructing Ureteric Calculi |
- | 4. Intractable Renal Colic Refractory to Maximal Parenteral Analgesia |
- | 5. Progressive Acute Kidney Injury or Anuria |
- +------------------------------------------------------------------------------------------------+
- 1. Obstructive Pyelonephritis and Urosepsis
An obstructing ureteric calculus in the presence of systemic infection (fever > 38.0 ∘ C > 38.0^\circ\text{C} > 38. 0 ∘ C , rigors, tachycardia, hypotension, pyuria, elevated CRP/procalcitonin) is an absolute, life-threatening urological emergency :
Pathophysiology : High pelvicalyceal pressure forces bacteria and endotoxins across the disrupted renal epithelial barrier into the systemic circulation via pyelovenous and pyelolymphatic backflow , precipitating fulminant septic shock, multi-organ dysfunction and death.
Decompression Modalities :
Retrograde Ureteral Double-J (JJ) Stenting under fluoroscopy, OR
Percutaneous Nephrostomy (PCN) tube placement.
Both methods are accepted and similarly effective for urgent decompression. Comparative evidence is limited; they do not have identical hospitalization or patient-experience outcomes. Selection depends on institutional availability, surgeon expertise, and patient stability (e.g., coagulopathy favors retrograde stenting; severe hemodynamic instability or retrograde failure favors PCN).
Caution
STRICT CONTRAINDICATION TO PRIMARY DEFINITIVE LITHOTRIPSY : Performing primary ureteroscopic stone extraction (URS) or laser lithotripsy in the setting of acute obstructive urosepsis is strictly contraindicated . Pressurized intrarenal irrigation during ureteroscopy dramatically escalates pyelovenous backflow, flooding the circulation with endotoxins and triggering catastrophic, fatal septic shock. The mandatory protocol is urgent emergency drainage (JJ stent or PCN) combined with broad-spectrum intravenous antibiotics , delaying definitive stone treatment until sepsis has resolved and infection has been treated. Timing follows clinical recovery.
2. Solitary or Transplanted Kidney Obstruction
Acute calculus obstruction of a solitary anatomical or functional kidney, or a renal allograft, can rapidly compromise the remaining renal function and may cause anuria, AKI and hyperkalemia. Obtain urgent specialist assessment and relieve clinically significant obstruction promptly.
3. Bilateral Obstructing Calculi
Produces acute bilateral post-renal failure requiring urgent unilateral or bilateral decompression.
4. Refractory Pain or Intractable Vomiting
Persistent, excruciating pain or intractable vomiting unresponsive to repeated maximal doses of parenteral NSAIDs and opioids requires urgent relief. EAU recommends decompression or ureteroscopic stone removal for analgesia-refractory colic; infection status and patient factors determine the approach.
Medical Expulsive Therapy (MET)
Medical Expulsive Therapy utilizes pharmacological agents to accelerate the spontaneous passage of ureteral calculi, alleviate colic symptoms, and reduce surgical intervention rates.
Pharmacological Mechanism: Alpha-1 Blockers
The human ureter is densely populated with alpha-1 adrenergic receptors , with the highest receptor concentration located in the distal ureter and intramural ureter (specifically the α 1 A \alpha_{1A} α 1 A and α 1 D \alpha_{1D} α 1 D receptor subtypes).
Alpha-1 Blockers (e.g., Tamsulosin 0.4 mg daily, Silodosin 8 mg daily) :
Antagonize alpha-1 receptors on ureteral smooth muscle cells.
Selectively abolish uncoordinated, hyperperistaltic spasms and basal smooth muscle tone.
Decrease intraureteral hydrostatic pressure immediately proximal to the stone while preserving coordinated propulsive peristaltic waves.
Dilate the distal ureter and ureterovesical junction, facilitating spontaneous passage and reducing pain.
Clinical Efficacy and Guideline Recommendations
Evidence is heterogeneous. SUSPEND found no overall reduction in four-week intervention needs with tamsulosin or nifedipine versus placebo. Other trials and pooled evidence support alpha-blockers particularly for larger distal stones, reflected in current EAU recommendations:
Distal Ureteral Stones 5–10 mm : Offer an alpha-blocker as one treatment option when active removal is not indicated. Benefit is greatest above 5 mm; do not apply one fixed relative benefit or passage-time reduction to every patient.
Calculi < 5 < 5 < 5 mm (Any Location) : MET provides no statistically significant advantage over placebo. Stones < 5 < 5 < 5 mm exhibit an intrinsically high spontaneous passage rate (75–85%) under simple observation alone.
Proximal and Mid-Ureteral Calculi : The evidence for MET in the proximal or mid-ureter remains weak and inconclusive; routine MET is not recommended for proximal stones.
Calcium Channel Blockers (e.g., Nifedipine) : Inhibit calcium influx into ureteral smooth muscle. While historically utilized, nifedipine is significantly less effective than tamsulosin and carries systemic hypotension risk; it is largely relegated to historical interest.
Patient Counseling and Adverse Effects
Stop MET and reassess urgently if infection, refractory pain or renal deterioration develops. Patients initiated on tamsulosin must be informed that MET represents an off-label use in many jurisdictions and counseled regarding potential adverse effects: ejaculatory dysfunction , orthostatic hypotension, dizziness, asthenia, and Intraoperative Floppy Iris Syndrome (IFIS) in patients planning cataract surgery.
Expectant Conservative Management & Safety Follow-Up
Conservative expectant management is appropriate for patients who meet all safety criteria:
Complete absence of clinical or laboratory signs of sepsis or urinary tract infection.
Adequate pain control achieved with oral analgesics.
Stable renal function with no indication for urgent relief of obstruction; a solitary kidney or bilateral obstruction warrants particular caution.
A stone with a reasonable chance of passage, considering size and location , with informed preference and reliable follow-up. There is no universal<6 mm eligibility cutoff.
Spontaneous Passage Dynamics
Spontaneous stone expulsion depends on two critical anatomical variables:
Size and Location Matter Together : EAU reports passage in almost 75% of stones<5 mm and 62% of stones≥5 mm overall, with an average expulsion time of about 17 days(range 6–29). These are cohort estimates, not individual guarantees.
Location : Reported passage is 49–52% for upper,58–70% for mid-ureteral and 68–83% for distal stones. For stones<5 mm, approximately 89% of distal and 71% of upper stones pass.
Passage becomes less likely as size increases, but >6 mm does not universally mean <15–20% passage . Persistent obstruction, pain, renal impairment or low passage likelihood favors active removal.
Follow-Up and Safety Net
Important
Expectant management must never be open-ended. Arrange clinical and imaging reassessment , for example within 2–4 weeks, tailored to obstruction, symptoms and renal risk. Confirm stone passage and recovery of renal function; lack of pain alone does not prove passage. EAU calls for periodic evaluation, not one universal maximum interval. Prolonged unmonitored observation risks "silent obstruction" —where the ureter adapts to chronic impaction and colic symptoms resolve, but ongoing high resistance causes insidious, irreversible renal cortical atrophy and permanent loss of renal function.
Clinical Triage, Pain Management, and Spontaneous Passage Dynamics
Parameter / Clinical Feature Clinical Criteria & Presentation EAU Guideline Recommended Management Scientific Rationale & Evidence Base Safety Warnings & Pitfalls
First-Line Analgesia Acute agonizing flank pain radiating to groin; afebrile; stable vitals NSAIDs : Diclofenac 75 mg IV/IM, Ketorolac 15–30 mg IV, or Indomethacin PR Inhibits renal prostaglandin synthesis; reduces renal blood flow and pelvicalyceal pressure; superior to opioids Contraindicated in CKD (eGFR < 30 < 30 < 30 ), active peptic ulcer, acute hypovolemic AKI
Rescue Analgesia Refractory colic pain despite maximal NSAID dose or NSAID contraindication Opioids : Morphine 5–10 mg IV or Hydromorphone; antiemetic co-prescription Acts on central mu-opioid receptors to blunt affective pain processing High rate of nausea, vomiting, dizziness, and sedation; does not reduce intrarenal pressure
Obstructive Sepsis / Pyelonephritis Calculus obstruction with fever > 38.0 ∘ C > 38.0^\circ\text{C} > 38. 0 ∘ C , rigors, tachycardia, hypotension Immediate Decompression via Retrograde JJ Stenting OR Percutaneous Nephrostomy High pressure causes pyelovenous backflow of endotoxins and bacteremia; drains infected space Primary definitive lithotripsy is STRICTLY CONTRAINDICATED ; delay definitive treatment until sepsis resolves and infection is treated
Medical Expulsive Therapy (MET) Selected distal ureteral stone 5–10 mm; afebrile, well-controlled pain, normal renal function Tamsulosin 0.4 mg PO daily (or Silodosin 8 mg daily) with planned reassessment Antagonizes distal ureteral α 1 A / α 1 D \alpha_{1A}/\alpha_{1D} α 1 A / α 1 D receptors; decreases basal tone and spasm; may improve passage, especially above 5 mm Little additional benefit for small stones; counsel about ejaculatory dysfunction, dizziness and IFIS; stop for complications
Expectant Observation (< 4 mm) Stone diameter < 4 < 4 < 4 mm; any ureteral location; pain well controlled Expectant observation with oral NSAIDs and hydration; strain urine High passage likelihood, influenced by location; no fixed individual expulsion deadline Arrange follow-up, often 2–4 weeks; confirm passage/renal recovery and return earlier for complications
Expectant Observation (4–6 mm) Stone diameter 4–6 mm; distal ureter; afebrile, pain controlled Observation; consider off-label tamsulosin for suitable distal stones>5 mm; strain urine Consider size/location and patient preference; alpha-blocker benefit is greatest for distal stones>5 mm Reassess persistent stone/obstruction and discuss active removal; intervene sooner for infection, uncontrolled pain or renal deterioration